Laird Thermal Systems Unveils Micro Multistage Thermoelectric Cooler & Optical TEAs Integration Capability

Laird Thermal Systems has developed the new OptoTEC™ MSX Series of micro multistage thermoelectric coolers and the capability to integrate them into various optical packages, including widely used TO-39, TO-46, or TO-8, creating advanced Optical Thermoelectric Assemblies (TEAs). The MSX Series utilizes advanced ceramic materials, proprietary solder bonding techniques and next-generation thermoelectric materials to boost cooling capacity by as much as 10% – all in a micro footprint. The Optical TEAs are designed for high-performance image sensing applications commonly used in analytical, industrial, and aerospace applications.

Thermal noise reduces image resolution as temperature increases. For high-end image sensing devices like IR detectors, X-ray detectors, CCD and CMOS sensors, deep cooling below ambient is required for the imaging sensor to capture maximum light spectrum.

The multistage MSX Series TECs offer micro footprints on the cold side down to 2.0 x 4.0 mm with thicknesses down to 3.3 mm for 2-stage, 3.8 mm for 3-stage and 4.9 mm for 4-stage coolers.

The packing fraction for thermoelectric elements enables a high heat pumping capacity up to 5 Watts, with lower operating currents than traditional multistage coolers. Featuring solid-state construction for long life reliability and no maintenance, the micro multistage thermoelectric coolers deliver reliable temperature stabilization from room temperature down to 180 Kelvin with no outgassing.

Manufactured in the USA, Laird Thermal Systems has invested in advanced automation equipment to integrate the multistage coolers into miniature optical packages in-house. This saves customers the burdensome task of integrating TECs into their packages, reducing assembly time and costs and improving repeatability.

“Advanced process automation has enabled a new level of miniaturization for our MSX multistage series to support next-generation imaging solutions that require smaller optical packages,” said Andrew Dereka, Thermoelectrics Product Director at Laird Thermal Systems. “Developing proprietary Optical TEA capabilities with minimal solder voiding ensures that our customers receive Optical TEAs with the highest quality, without the hassle of building assemblies themselves.”

The MSX Series is undergoing Telcordia GR-468 CORE qualification to ensure high repeatability and long-life operation in optical environments. More here.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.